In melanoma, CDK1 collaborates with Sox2 to promote tumor initiation (24), while in gastrointestinal stromal tumors, CDK1 emerges as a novel vulnerability independent of the cell cycle, offering potential therapeutic avenues for advanced-stage patients (25). This evidence concerns the gene SOX2 and neoplasm.